Nivolumab for the treatment of cancer

Bibliography

• Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 2007;19:309-14
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99:12293-7
   PubMed Web of Science ®Google Scholar
• Srivastava N, McDermott D. Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manag Res 2014;6:279-89
   PubMed Web of Science ®Google Scholar
• Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007;13(6):1757-61
   PubMed Web of Science ®Google Scholar
• Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004;101:17174-9
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmodynamics, and immunologic correlates. J Clin Oncol 2010;28(19):3167-75
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective re-induction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013;19(2):462-8
   PubMed Web of Science ®Google Scholar
• Weber JS, Minor D, D’Angelo SP, et al. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma with prior anti-CTLA-4 therapy [abstract LBA3]. EMSO 2014
   Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33
   PubMed Web of Science ®Google Scholar
• Sznol M. Survival, response duration, and activity by BRAF mutation status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab concurrent therapy in advanced melanoma [abstract #9003]. ASCO 2014
   Google Scholar
• Topalian SL. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a Phase I trial [abstract #3002]. ASCO 2013
   Google Scholar
• Drake CG. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a Phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up [abstract #4514]. ASCO 2013
   Google Scholar
• Motzer RJ. Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging Phase II trial [abstract #5009]. ASCO 2014
   Google Scholar
• Hammers HJ. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma [abstract #4504]. ASCO 2014
   Google Scholar
• Amin A. Nivolumab in combination with sunitinib or pazopanib in patients with metastatic renal cell carcinoma [abstract #5010]. ASCO 2014
   Google Scholar
• Brahmer JR. Nivolumab in patients with advanced non-small ell lung cancer: Survival and clinical activity by subgroup analysis [abstract #8112]. ASCO 2014
   Google Scholar
• Gettinger SN. First-line nivolumab monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status [abstract #8024]. ASCO 2014
   Google Scholar
• Antonia SJ. Nivolumab and ipilimumab in first-line NSCLC: Interim Phase I results [abstract #8023]. ASCO 2014
   Google Scholar
• Antonia SJ. Nivolumab in combination with platinum-based doublet chemotherapy in advanced non-small cell lung cancer [abstract #8113]. ASCO 2014
   Google Scholar
• Rizvi NA. Safety and response with nivolumab plus erlotinib in patients with epidermal growth factor receptor mutant advanced NSCLC [abstract #8022]. ASCO 2014
   Google Scholar
• Hamanishi J. Efficacy and safety of anti-PD-1 antibody in patients with platinum-resistant ovarian cancer [abstract #5511]. ASCO 2014
   Google Scholar
• Grosso J. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) [abstract #3016]. ASCO 2013
   Google Scholar
• Hodi S. Long-term survival of ipilimumab-naïve patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a Phase I trial [abstract #9002]. ASCO 2014
   Google Scholar
• Choueiri TK. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial [abstract #5012]. ASCO 2014
   Google Scholar
• Powderly JD. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study [abstract #3001]. ASCO 2013
   Google Scholar